Amgen Inc. $AMGN Shares Acquired by Vickerman Investment Advisors Inc.

Vickerman Investment Advisors Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN) by 12.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,489 shares of the medical research company’s stock after acquiring an additional 1,741 shares during the quarter. Vickerman Investment Advisors Inc.’s holdings in Amgen were worth $4,371,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 2nd quarter valued at about $27,000. Evelyn Partners Investment Management LLP acquired a new position in Amgen during the second quarter valued at approximately $32,000. Howard Hughes Medical Institute purchased a new stake in Amgen during the second quarter worth approximately $32,000. Quaker Wealth Management LLC increased its position in shares of Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after acquiring an additional 240 shares in the last quarter. Finally, Nvwm LLC raised its stake in shares of Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 134 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the subject of several recent research reports. The Goldman Sachs Group increased their price target on Amgen from $400.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Royal Bank Of Canada increased their target price on Amgen from $330.00 to $335.00 and gave the company an “outperform” rating in a research note on Thursday, January 8th. Scotiabank started coverage on Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price on the stock. Cantor Fitzgerald upped their price target on Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Finally, BMO Capital Markets increased their price objective on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus price target of $339.71.

Amgen Trading Down 2.6%

Shares of AMGN opened at $342.22 on Thursday. Amgen Inc. has a one year low of $261.43 and a one year high of $353.25. The stock has a 50-day moving average price of $332.38 and a 200 day moving average price of $308.67. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The company has a market capitalization of $184.28 billion, a P/E ratio of 26.45, a P/E/G ratio of 3.11 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the business posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is presently 73.57%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 10,908 shares of company stock valued at $3,674,966. Insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.